WHAT IS CLAIMED IS:

1. A compound of formula I



I

and the pharmaceutically acceptable salts, esters and tautomers thereof, wherein

R^1 is selected from the group consisting of:

(a) $-CF_3$,

(b) $-CH_2C(CH_3)_3$,

(c) phenyl, unsubstituted, mono- or poly- substituted with halo,

(d) $-C_{1-6}$ alkyl, and

(e) $-C_{1-2}$alkyl-phenyl;

R^2 is selected from the group consisting of:

(a) $-C_{1-6}$ alkyl,

(b) $-COOR^3$,

(c) $-CR^3R^4$-O-R^5,

(d) $-CR^3R^4$-S-R^5, and

(e) $-COR^3$;

R^3, R^4 and R^5 are independently selected at each occurrence from the group consisting of -H, phenyl, and C_{1-6} alkyl;

Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  and (v)  ,

(b) a 6-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  (v)  (vi) 

(vii)  and (viii)  ,

(c)



, and

(d) a bicyclic heterocyclic ring selected from the group consisting of:

(i) 

(ii) 

(iii) 

(iv) 

and (v) 

,

wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R^7;

R^6 is independently selected at each occurrence from the group consisting of:

(a) –H,

(b) –C_{1-6}alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -NR^3R^4, -OR^3, -$COOR^3$, and –CN,

(c) –C_{1-6}alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(d) –C_{3-6}cycloalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -OR^3, -$COOR^3$, and –CN,

(e) –C_{3-6}cycloheteroalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -$(CH_2)_nOR^3$, -OR^3, -$COOR^3$, and –CN, wherein n is an integer selected from 2, 3, 4, 5 and 6,

(f) –C_{2-6}alkenyl,

(g) –$C(O)C_{1-6}$alkyl,

(h) –$COOR^3$,

(i) –$C(O)$–$(CH_2)_p$–$COOR^3$, wherein p is an integer selected from 2, 3 and 4,

(j) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(k) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(l) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(m) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$, and

(n) thiazolyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$;

R^7 is independently selected at each occurrence from the group consisting of:

(a) =O,

(b) –C_{1-6}alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –CN, –$COOR^3$, –COR^3, and –OH,

(c) –C_{1-6}alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –OH, –$COOR^3$, tetrazole and –CN,

(d) –C_{3-6} cycloalkyl,

(e) –C_{3-6} spiroalkyl,

(f) –$COOR^3$,

(g) halo,

(h) –NR^3R^4,

(i) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –$COOR^3$ and –C_{1-4}alkyl,

(j) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(k) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$, and

(l) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$; and

Z is selected from the group consisting of:

(a) –C_{1-6}alkyl-,

(b) –C_{1-6}alkyl-O-,

(c) –C_{3-6}cycloalkyl-, and

(d) –C_{3-6}cycloalkyl-O-.

2. A compound of formula I



I

and the pharmaceutically acceptable salts, esters and tautomers thereof, wherein

R^1 is selected from the group consisting of:

(a) $-CF_3$,

(b) $-CH_2C(CH_3)_3$,

(c) phenyl, unsubstituted, mono- or poly- substituted with halo,

(d) $-C_{1-6}$ alkyl, and

(e) $-C_{1-2}$alkyl-phenyl;

R^2 is selected from the group consisting of:

(a) $-C_{1-6}$ alkyl,

(b) $-COOR^3$,

(c) $-CR^3R^4$-O-R^5,

(d) $-CR^3R^4$-S-R^5, and

(e) $-COR^3$;

R^3, R^4 and R^5 are independently selected at each occurrence from the group consisting of -H, phenyl, and C_{1-6} alkyl;

Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  and (v)  ,

(b) a 6-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  (v)  (vi) 

(vii)  and (viii)  ,

provided that when R_1 is $-CF_3$, R_2 is n-propyl, and Z is n-propyloxy, the 6-membered heterocyclic ring is not unsubstituted 5,6 dihydrouracil,

(c)

 , and

(d) a bicyclic heterocyclic ring selected from the group consisting of:

(i) 

(ii) 

(iii) 

(iv) 

and (v)  ,

wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R^7;

R^6 is independently selected at each occurrence from the group consisting of:

(a) –H,

(b) $-C_{1-6}$alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, $-NR^3R^4$, $-OR^3$, $-COOR^3$, and –CN,

(c) $-C_{1-6}$alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$,

(d) –C_{3-6}cycloalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -OR^3, -$COOR^3$, and –CN,

(e) –C_{3-6}cycloheteroalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -$(CH_2)_nOR^3$, -OR^3, -$COOR^3$, and –CN, wherein n is an integer selected from 2, 3, 4, 5 and 6,

(f) –C_{2-6}alkenyl,

(g) –$C(O)C_{1-6}$alkyl,

(h) –$COOR^3$,

(i) –$C(O)$–$(CH_2)_p$–$COOR^3$, wherein p is an integer selected from 2, 3 and 4,

(j) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(k) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(l) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(m) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$, and

(n) thiazolyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$;

R^7 is independently selected at each occurrence from the group consisting of:

(a) =O,

(b) –C_{1-6}alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –CN, –$COOR^3$, –COR^3, and –OH,

(c) –C_{1-6}alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –OH, –$COOR^3$, tetrazole and –CN,

(d) –C_{3-6} cycloalkyl,

(e) –C_{3-6} spiroalkyl,

(f) –$COOR^3$,

(g) halo,

(h) –NR^3R^4,

(i) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –$COOR^3$ and –C_{1-4}alkyl,

(j) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$,

(k) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$, and

(l) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –C_{1-3}alkyl, and –$COOR^3$; and

Z is selected from the group consisting of:

(a) –C_{1-6}alkyl-,

(b) –C_{1-6}alkyl-O-,

(c) –C_{3-6}cycloalkyl-, and

(d) –C_{3-6}cycloalkyl-O-.

3. The compound of claim 1 wherein Z is -C_{2-4}alkyl-O-.

4. The compound of claim 3 wherein

R^1 is selected from the group consisting of:

(a) –CF_3,

(b) –$CH_2C(CH_3)_3$, and

(c) phenyl, unsubstituted, mono- or poly- substituted with halo; and

R^2 is selected from the group consisting of:

(a) $-C_{1-6}$ alkyl, and

(b) $-COR^3$.

5. The compound of claim 4 wherein R^2 is n-propyl.

6. The compound of claim 5 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  and (v)  ,

(b) a 6-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  (iii) 

(iv)  (v)  and (vi)  ,

(c)



, and

(d)



,

wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R^7.

7. The compound of claim 6 wherein R^6 is independently selected at each occurrence from the group consisting of:

(a) –H,

(b) $-C_{1-6}$alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, $-NR^3R^4$, $-OR^3$, $-COOR^3$, and –CN,

(c) $-C_{1-6}$alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$,

(d) $-C(O)-(CH_2)_p-COOR^3$, wherein p is an integer selected from 2, 3 and 4,

(e) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$,

(f) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$, and

(g) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$.

8. The compound of claim 7 wherein R^7 is independently selected from the group consisting of:

(a) =O,

(b) $-CH_2$-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –CN, $-COOR^3$, $-COR^3$, and –OH,

(c) $-C_{1-6}$alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, –OH, $-COOR^3$, tetrazole and –CN,

(d) halo,

(e) $-NH_2$,

(f) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-COOR^3$ and $-C_{1-4}$alkyl, and

(g) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$alkyl, and $-COOR^3$.

9. The compound of claim 3 wherein R^1 is selected from the group consisting of:

(a) $-CF_3$, and

(b) phenyl, unsubstituted, mono- or poly- substituted with halo.

10. The compound of claim 9 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:

(i)  (ii) 

(iii)  and (iv)  ,

(b) a 6-membered heterocyclic ring selected from the group consisting of:

(i)  (ii)  and (iii)  ,

(c)

 , and

(d)

 ,

wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R^7.

11. The compound of claim 3 wherein R^1 is $-CF_3$.

12. The compound of claim 11 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:

(i)  and (ii)  , and

(b) a 6-membered heterocyclic ring selected from the group consisting of:

(i)  and (ii)  ,

wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R^7.

13. The compound of claim 1 wherein Z is $-C_{3-6}$cycloalkyl-O-.

14. The compound of claim 1 wherein Z is $-C_{4-6}$alkyl-.

15. A compound selected from:

(1) 1-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;

(2) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;

(3) 2-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1*H*-isoindole-1,3(2*H*)-dione;

(4) 3,3-dimethyl-1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;

(5) 3-methyl-3-phenyl-1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;

(6) 3-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)thiazolidine-2,4-dione;

(7) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)thiazolidine-2,4-dione;

(8) 5,5-dimethyl-3-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)thiazolidine-2,4-dione;

(9) [2,4-dioxo-3-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1,3-thiazolidin-5-yl]acetic acid;

(10) 3-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(11) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(12) 1-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(13) 5(R)-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(14) 5,5-dimethyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(15) 1-(2-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(16) 5-methyl-5-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(17) 5-methyl-5-phenyl-3-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(18) 5-methyl-5-phenyl-3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(19) 5-methyl-5-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}butyl)imidazolidine-2,4-dione;

(20) 5-methyl-5-(3-carboxyphenyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(21) 5-methyl-5-(4-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(22) 5-methyl-5-(3-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(23) 5-methyl-5-(2-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(24) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1-pyrimidin-2-ylimidazolidine-2,4-dione;

(25) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1-pyrazin-2-ylimidazolidine-2,4-dione;

(26) 3-[2,5-dioxo-4-phenyl-1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-4-yl]propanoic acid;

(27) 4-[5,5-dimethyl-2,4-dioxo-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-1-yl]butanoic acid;

(28) 4-[5,5-dimethyl-2,4-dioxo-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-1-yl]pentanoic acid;

(29) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-2-one;

(30) methyl 2-[2-oxo-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-1-yl]propanoate;

(31) 2-[2-oxo-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-1-yl]propanoic acid;

(32) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(33) 5,5-dimethyl-1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(34) 1-[*cis*-2-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclohexyl)methyl]dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(35) 1-[*trans*-2-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclopentyl)methyl]dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(36) 1-{4-[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(37) 5-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(38) 6-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(39) 5-Methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(40) 1,5-Dimethyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(41) 1-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(42) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1-pyridin-2-yldihydropyrimidine-2,4(1*H*,3*H*)-dione;

(43) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-5,6-dihydro-2*H*-1,2'-bipyrimidine-2,4(3*H*)-dione;

(44) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-5,6-dihydro-2*H*-1,5'-bipyrimidine-2,4(3*H*)-dione;

(45) 1-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2-one;

(46) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2-one;

(47) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,6-dione;

(48) 1-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,5-dione;

(49) 4-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)morpholine-3,5-dione;

(50) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperazine-2,5-dione;

(51) 4-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperazine-2-one;

(52) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1,3,5-triazinane-2,4-dione;

(53) 3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(54) 6-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione; and

(55) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)azepan-2-one;

and pharmaceutically acceptable salts, esters and tautomers thereof.

16. The compound according to Claim 15 selected from:

(1) 11-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-2-one;

(2) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;

(3) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)thiazolidine-2,4-dione;

(4) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(5) 1-Methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(6) 5,5-dimethyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(7) 1-Phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(8) 1-(2-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(9) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(10) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}butyl)imidazolidine-2,4-dione;

(11) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(12) 5-(3-carboxyphenyl)-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(13) 5-(2-Pyridyl)-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(14) 5-Phenyl-5-(3-propionyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

(15) 2-[2-oxo-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-1-yl]propanoic acid;

(16) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2-one;

(17) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,6-dione;

(18) 1-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,5-dione;

(19) 1-[*cis*-2-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclohexyl)methyl]dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(20) 3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(21) 6-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(22) 1-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;

(23) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1-pyridin-2-yldihydropyrimidine-2,4(1*H*,3*H*)-dione;

(24) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-5,6-dihydro-2*H*-1,2'-bipyrimidine-2,4(3*H*)-dione; and

(25) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)azepan-2-one;

and pharmaceutically acceptable salts, esters and tautomers thereof.

17. A method for treating dyslipidemia comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.

18. The method of claim 17 wherein the dyslipidemia comprises depressed plasma HDL cholesterol level.

19. A method for treating atherosclerosis comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.

20. A method for reducing the risk of occurrence of atherosclerosis comprising administering a prophylactically effective amount of a compound of claim 1 to a patient at risk for developing atherosclerosis.

21. A method for reducing the risk of occurrence of an atherosclerotic disease event comprising administering a prophylactically effective amount of a compound of claim 1 to a patient at risk for having an atherosclerotic disease event.

22. A method for slowing the progression of atherosclerotic disease comprising the administration of a therapeutically effective amount of a compound of Formula I to a patient who has atherosclerotic disease.

23. A method for removing cholesterol from tissue deposits comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.

24. A method for preventing lipid accumulation in tissue deposits comprising administering a prophylactically effective amount of a compound of claim 1 to a patient in need thereof.

25. A pharmaceutical composition comprised of a compound of claim 1 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition made by combining a compound of claim 1 with a pharmaceutically acceptable carrier.

27. A process for preparing a pharmaceutical composition comprising combining a compound of Formula I with a pharmaceutically acceptable carrier.

28. The use of a compound of claim 1 for the manufacture of a medicament useful for the treatment of a disease mediated by the LXR receptor in a human patient in need of such treatment.

29. The use of a compound of claim 1 for the manufacture of a medicament useful for the prevention of a disease mediated by the LXR receptor in a human patient in need of such treatment.